Zaltoprofen, a selective cyclooxygenase-2 (COX-2) inhibitor and a member of the nonsteroidal anti-inflammatory drugs, has been associated with the formation of nitrosamine impurities under specific conditions involving secondary or tertiary amines and nitrite salts, particularly in acidic environments. This research presents a detailed, exacting, and structured analytical approach for quantifying nine nitrosamine impurities (N-Nitroso dimethyl amine, N-Nitroso- N-methyl-4-aminobutyric acid, N-Nitroso diethyl amine, N-Nitroso morpholine, N-Nitrosoethylisopropylamine, N-Nitroso diisopropylamine, N-Nitrosomethylphenylamine, N-Nitroso dibutyl amine, and 1-Methyl-4- Nitrosopiperazine) utilizing the Acquity UPLC HSS T3 (100 x 3.0 mm, 1.8μ) column on the Waters UHPLC-MS/ MS Acquity H-Class platform. The method established a gradient program utilizing 0.1% formic acid and methanol as mobile phases A and B, respectively, at a flow rate of 0.5 ml/minutes, with ionization performed using atmospheric pressure chemical ionization in positive mode. Quantification was performed utilizing multiple reaction monitoring mode, achieving sensitivity at the parts per million (ppm) level. The validation of the proposed analytical method adhered to the guidelines established by the International Council for Harmonisation Q2, incorporating parameters such as system precision, specificity, linearity (R² > 0.990 from limit of quantification (LOQ) to 200%), accuracy, method precision, intermediate precision, limit of detection (0.0014 ppm), and LOQ (0.0041 ppm) for the nine nitrosamine impurities. The method further assesses environmental sustainability through the Analytical GREEnness and Analytical Eco-Scale evaluations, which validated the method’s commendable eco-friendliness. This thorough approach highlights the essential requirement for the oversight of nitrosamine impurities in active pharmaceutical ingredients to uphold safety and conformity with regulatory standards.
Rani Satla S, Gunda R. A sensitive green analytical LC-MS/MS method for the quantification of trace level of nine nitrosamine impurities in Zaltoprofen bulk drug. 2025. Article in Press. http://doi.org/10.7324/JAPS.2026.244232
1. Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K. Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006;54:288–94. doi: https://doi.org/10.1016/j.neures.2005.12.016.
2. Higuchi T, Takeuchi A, Munesue S, Yamamoto N, Hayashi K, Harashima A, et al. A nonsteroidal anti-inflammatory drug, zaltoprofen, inhibits the growth of extraskeletal chondrosarcoma cells by inducing PPARγ, p21, p27, and p53, Cell Cycle. 2023; 22:939–50. doi: https://doi.org/10.1080/15384101.2023.2166195.
3. Muruganantham S, Krishnaswami V, Kandasamy R, Alagarsamy S. Potentiating the solubility of BCS class II drug zaltoprofen using nanodispersion technology. J Dispers Sci Technol. 2024;45:632–41. doi: https://doi.org/10.1080/01932691.2023.2173224.
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Control of Nitrosamine Impurities in Human Drugs Guidance for Industry. 2024. Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
5. M7(R2) Addendum: Application of the principles of the ICH M7 guideline to calculation of compound-specific Acceptable Intakes Guidance for Industry. 2023. Available from: https://www.regulations.gov/docket/FDA-2022-D-0055
6. Nitrosamine impurities in drugs: what health care professionals need to know.
7. Recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs). Guidance for Industry, 2023.
8. Bhukya VN, Beda DP. Implementation of green analytical principles to develop and validate the HPLC method for the separation and identification of degradation products of Panobinostat, and its characterization by using LC-QTOF-MS/MS and its in-silico toxicity prediction using ADMET software. Green Anal Chem. 2024;8:100090. doi: https://doi.org/10.1016/j.greeac.2023.100090.
9. Divya Bhargavi P, Lolla S, Sugunan S, Shiva Gubbiyappa K, Ali Khan A, Alanazi AM, et al. The simultaneous quantification of Sitagliptin and Irbesartan in rat plasma using the validated LC-MS/MS method is applied to a pharmacokinetic study. J Chromatogr B. 2023;1221:123677. doi: https://doi.org/10.1016/j.jchromb.2023.123677.
10. Bhukya VN, Beda DP, Gubbiyappa KS, Pathuri R. Combined green analytical principles and quality by design for ultraperformance liquid chromatography analytical method development, the characterization and in-silico toxicity prediction of Ixazomib degradation products using mass spectrometry. Green Anal Chem. 2024;8:100105. doi: https://doi.org/10.1016/j.greeac.2024.100105.
11. Boovizhikannan T, Nagaraja S, Petapalli B, Shankar PM, Sampath K. Reported estimation techniques for quantification of zaltoprofen: a review. World J Bio Pharm Health Sci. 2022;12:30–9. doi: https://doi.org/10.30574/wjbphs.2022.12.2.0188.
12. Deshpande MM, Kasture VS, Mohan M, Chavan MJ.Development and validation of RP-HPLC method and forced degradation of powerful bradykinin inhibitor zaltoprofen. CPA. 2018;14:604–10. doi: https://doi.org/10.2174/1573412913666171005161737.
13. Bhosale VM, Sonvane SM, Birajdar MJ, Satpute KL, Shetkar BM, Gadgul AB, et al. RP-HPLC method development and validation for of paracetamol & zaltoprofen in pharmaceutical dosage form. IJBPAS. 2024;13:9634. doi: https://doi.org/10.31032/IJBPAS/2024/13.11.9634.
14. Jang J-H, Jeong SH, Cho H-Y, Lee Y-B. Comparison of UPLC-MS/MS and HPLC-UV methods for the determination of zaltoprofen in human plasma. J Pharm Investig. 2019;49:613–24. doi: https://doi.org/10.1007/s40005-018-00416-w.
15. Yang HK, Kim SY, Kim JS, Sah H, Lee HJ.Application of column-switching HPLC method in evaluating pharmacokinetic parameters of zaltoprofen and its salt. Biomed Chromatogr. 2009;23:537–42. doi: https://doi.org/10.1002/bmc.1151.
16. Chu VM, Kim KT, Kim SH, Lee W, Lee KC, Nguyen VL, et al. Chiral pharmacokinetics of zaltoprofen in rats by HPLC with solid-phase extraction. J Pharm Biomed Anal. 2012;70:567–73. doi: https://doi.org/10.1016/j.jpba.2012.05.019.
17. Patil JD, Dhankani AR, Pawar SP. Spectrophotometric and chromatographic review on NSAIDs include: zaltoprofen, loxoprofen, ketoprofen and flurbiprofen. AJPA. 2023;11:261–6. doi: https://doi.org/10.52711/2231-5675.2023.00043.
18. ICH. Harmonised Tripartite guideline validation of analytical procedures: text and methodology Q2(R1), 2005.
Year
Month